Cover Image
市場調查報告書

處方藥改列成藥的機會:OTC趨勢,類別分析,案例研究,未來的機會

Rx-OTC Switch Opportunities : Trends in OTC, category analysis, case studies and future opportunities

出版商 Canadean 商品編碼 344930
出版日期 內容資訊 英文 79 Pages
訂單完成後即時交付
價格
Back to Top
處方藥改列成藥的機會:OTC趨勢,類別分析,案例研究,未來的機會 Rx-OTC Switch Opportunities : Trends in OTC, category analysis, case studies and future opportunities
出版日期: 2015年02月28日 內容資訊: 英文 79 Pages
簡介

受惠於向上成長的數年後,製藥產業面臨著現象比較嚴重情形。新藥的開發成本的增加,法規的壓力,以及生命週期管理的利用,由於成本意識變得高的製藥產業,到現在為止在以上發揮重要作用。

從本報告提供處方藥改列成藥 (醫療用一般用轉換的醫藥品) 調查分析,潛在性高的產品,產品類型分析,案例研究等系統性資訊。

第1章 簡介

第2章 處方藥改列成藥:新的成長範例

  • 摘要
  • OTC市場演進

第3章 OTC交換器趨勢

  • 摘要
  • 對交換器最適合的類別
  • 類別的演進
  • 風險的管理
  • OTC的銷售

第4章 未來的產品和各類別的機會

  • 摘要
  • 選恰當的產品
  • 未來的交換器

第5章 OTC交換器的成長市場

  • 摘要
  • 簡介
  • 主要的市場
  • 成長新興市場牽引
  • OTC交換器的潛在成長市場
    • 西歐市場
      • 日本
      • 英國
      • 美國
    • 新興市場
      • 中國
      • 巴西
      • 印尼
  • 人口統計的變化生出新的成長機會
  • OTC企業和交換器形勢

附錄

圖表

目錄
Product Code: CS1005IS

Summary

After years of buoyant growth, the pharmaceutical industry is facing up to a more challenging time. With the growing cost of developing novel drugs, combined with rising regulatory pressures, the use of lifecycle management is playing an ever-more important role in the increasingly cost-conscious pharma industry. This report identifies actual opportunities in OTC switching.

Key Findings

  • The pharmaceutical market is changing. Since 2007, sales of OTC drugs have outstripped those for their prescription counterparts. Whereas once consumer health products were seen as a lucrative sideline, they are becoming a major focus for pharmaceutical companies. Between 2008 and 2013, worldwide OTC growth averaged 6.5% compared to 4.5% for Rx.
  • Creating new categories can be fraught with risk. This was shown by the attempts of GSK to introduce the weight-loss therapy area with its Alli (orlistat 60mg capsules). After a promising start, sales collapsed due to concerns over both efficacy and safety.
  • With a large and rapidly expanding population, Indonesia is catching the eye of Western multinationals in a number of industries. Within the pharma industry, self-medication is well established and these drugs account for 40% of drug spending.

This report takes an in-depth look at the market for Rx-OTC switches. It considers which categories have the most potential for switching, analyzing both past performance and expected future outcomes, and then examines specific candidates.

Reasons To Buy

  • Identify products that have the most Rx-OTC switching potential.
  • Analyze the product categories that are changing the Rx-OTC environment.
  • Understand why some key Rx-OTC switches have failed.
  • Use case studies to assess the revenues generated by successful switches.

Table of Contents

Suzanne Elvidge

  • Disclaimer

Executive summary

  • Rx-OTC: the new growth paradigm
  • OTC switch trends
  • Future product and category opportunities
  • Growth markets for OTC switching

Chapter 1 - Introduction

  • OTC market overview
    • About this report

Chapter 2 - Rx-OTC: the new growth paradigm

  • Summary
  • OTC market evolution
    • Extending the lifecycle
    • Technology is broadening the horizons for OTC drugs
    • Major tech companies entering the space
    • NSURE to impact the regulatory pathways
    • Harmonization in the EU
    • Frameworks in the rest of the world
    • Advertising is a controversial issue

Chapter 3 - OTC switch trends

  • Summary
  • Categories best suited for switching
  • Category evolution
    • Cough and cold has traditionally been a strong area for OTC drugs
    • Emergence of allergy treatments
    • Anti-fungals making an impact
  • Managing risk
    • Contraception
    • Slow take-up of weight-loss drug highlights the risks of switching
  • OTC launches falling into similar categories

Chapter 4 - Future product and category opportunities

  • Summary
  • Picking the right product
    • The importance of innovation
    • Buying into the brand
    • Form and function
  • Switching in the future
    • Acid reflux/acid indigestion
    • Cialis and Viagra are strong candidates in erectile dysfunction
    • Hair loss looking bare for new products
    • Imitrex an interesting candidate for migraine
    • Current nausea OTCs ineffective
    • Safety concerns hampering osteoporosis switches
    • Overactive bladder: opportunity with obstacles
    • Raised cholesterol, raising hopes for statin switches
  • Analysis of products with greatest switch potential

Chapter 5 - Growth markets for OTC switching

  • Summary
  • Introduction
  • Selecting markets
  • Growth driven by emerging markets
  • Potential growth markets for OTC switches
    • Western markets
      • Japan
      • UK
      • US
    • Emerging markets
      • China
      • Brazil
      • Indonesia
  • Changing demographics creating new growth opportunities
    • Pediatric OTCs
    • Kid care a growing market
    • Elderly care a growing opportunity
    • Ease of use is important for elderly patients
  • OTC companies and the switch landscape

Appendix

  • Methodology
  • Bibliography/references
    • Chapter 1
    • Chapter 2
    • Chapter 3
    • Chapter 4
    • Chapter 5

Table of figures

  • Figure 1: Benefits of Rx-OTC switching
  • Figure 2: Pharma market growth (%), 2003--13
  • Figure 3: Skinvision app for detecting cancerous moles
  • Figure 4: SoloHealth Kiosk allows self-screening of blood pressure and other health indicators
  • Figure 5: Nike FuelBand + Apple iWatch help consumers to track health indicators
  • Figure 6: US OTC switches by indication, 1976--2014
  • Figure 7: Leading new OTC allergy treatments
  • Figure 8: Monistat, same active ingredient different branding and indications
  • Figure 9: Plan B OTC contraception
  • Figure 10: Alli OTC version
  • Figure 11: Breakdown of contribution to European OTC growth based on five-year sales, 2009--13
  • Figure 12: Growth of value share and price premium of new products across key European OTC categories in 2013
  • Figure 13: Nexium 24HR and Prilosec OTC, leading heartburn treatments
  • Figure 14: Top 10 OTC brands by revenue in the US in 2013
  • Figure 15: Examples of erectile dysfunction drugs available from an online pharmacy in the UK
  • Figure 16: Oxytrol for Women OTC version
  • Figure 17: Global OTC market -- share of sales and share of growth, 2013
  • Figure 18: OTC approvals in Japan, 1983--2014
  • Figure 19: European OTC sales, 2011--13
  • Figure 20: OTC approvals in the US, 1976--2014
  • Figure 21: Lycotec chocolate delivery platform could be used for pediatric OTCs

Table of tables

  • Table 1: FDA Rx-OTC switches, 2009--14
  • Table 2: Potential new OTC candidates due to NSURE
  • Table 3: Examples of recent switches worldwide, 2012--14
  • Table 4: Recent and upcoming patent expiries for key drugs
  • Table 5: Potential major OTC switches in the next five years
  • Table 6: OTC sales by region ($bn), 2013
  • Table 7: Potential growth markets for OTC launches
  • Table 8: Top five OTC companies, ($bn), 2013
Back to Top